Alopecia area (AA) is a common autoimmune disorder, characterized by hair loss. Although
its impact on quality of life is fairly well understood, studies on the economic impact of AA are …

Introduction: Patients with alopecia areata (AA) report high levels of dissatisfaction with
commonly used treatments. Patient-reported outcomes are essential to understanding …

Background For many decision makers in Health Technology Assessment the EQ-5D-5L is
the standard measure of health-related quality of life (HRQL). However, evidence has shown …

Purpose Traditionally, appropriate anchors are used to investigate the amount of change on
a clinician-reported outcome assessment that is meaningful to individual patients. However …

Alopecia areata (AA) is a non‐scarring hair loss disorder affecting approximately 2% of the
global population. AA is reported to have a significant negative impact on the emotional and …

Purpose Alopecia areata (AA) is an autoimmune-mediated inflammatory dermatological
disease characterised by non-scarring hair loss affecting the scalp and sometimes other hair …

Background The content validity (appropriateness and acceptability) of patient‐reported
outcome (PRO) measures for scalp hair loss, eyebrow loss, eyelash loss, nail damage and …

Background ALLEGRO‐LT is an ongoing, long‐term, open‐label, multicentre, phase 3 study
of ritlecitinib in adults and adolescents with alopecia areata (AA). Objectives To evaluate …

Introduction Patients with alopecia areata (AA) may have received several therapies for
management of AA during their lives. In the ALLEGRO phase 2b/3 (NCT03732807) study …

This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the
efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in …